Antitumor effect of humanized anti-interleukin-6 receptor antibody (tocilizumab) on glioma cell proliferation. Laboratory investigation.

  title={Antitumor effect of humanized anti-interleukin-6 receptor antibody (tocilizumab) on glioma cell proliferation. Laboratory investigation.},
  author={Mareina Kudo and Hirofumi Jono and Satoru Shinriki and Shigetoshi Yano and Hideo Nakamura and Keishi Makino and Takuichiro Hide and Daisuke Muta and Mitsuharu Ueda and Kazutoshi Ota and Yukio Ando and Jun-ichi Kuratsu},
  journal={Journal of neurosurgery},
  volume={111 2},
OBJECT Interleukin-6 (IL-6) is a pleiotropic cytokine that regulates diverse physiological functions, including cell proliferation and survival. Recent studies have shown that IL-6 expression is often elevated in response to several types of glioma. Although IL-6 is said to play an important role in glioma, the involvement of IL-6 signaling has been quite controversial. The aim of this study was to evaluate the involvement of IL-6 signaling in glioma and the inhibitory effect of IL-6 signaling… 

Figures from this paper

Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells.

Findings indicate that IL-6R is present in CSCs and has an important role in the proliferation and development of CSC-directed lung cancer in the H460 lung cancer cell line.

Gr upSM Interleukin-6 as a Therapeutic Target on Human Cancer

Clinical studies on tocilizumab (anti-IL-6R) for treatment of cancer, combination therapy with IL-6 blockade and conventional drugs achieved better treatment efficacy and patient responses compared to monotherapy.

Anti-proliferative action of IL-6R-targeted antibody tocilizumab for non-small cell lung cancer cells.

Overall, these data indicate that tocilizumab has anticancer potency via apoptosis induction as an agonistic IL-6R regulator and suggest that this anti-IL- 6R antibody may be utilized as a new targeting molecule for NSCLC therapies.

Tocilizumab unmasks a stage-dependent interleukin-6 component in statin-induced apoptosis of metastatic melanoma cells

Results confirm that simvastatin facilitates apoptosis in combination with IL-6, and may explain the failure of simVastatin to reduce melanoma incidence in clinical trials and meta-analyses.

Inhibition of STAT3 Signaling Blocks the Anti-apoptotic Activity of IL-6 in Human Liver Cancer Cells*

The results demonstrated that targeting STAT3 signaling could interrupt the anti-apoptotic function of IL-6 in human liver cancer cells.

Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.

IL-6/IL-6R pathway is a therapeutic target in chemoresistant ovarian cancer

It is suggested that blockade of the IL-6 signaling pathway with anti-IL-6 receptor antibody tocilizumab might resensitize the chemoresistant cells to the current chemotherapeutic agents.

Tumor-related interleukins: old validated targets for new anti-cancer drug development

An overview of the current understanding of the role of the best-validated cytokines involved in tumor progression, IL-1,IL-4 and IL-6; in addition to IL-2 cytokines family, which is known to promote tumor eradication by immune cells, are provided.

Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies

The role of IL-6 in bone metabolism, in cancer metastasis to bone, 3) in cancer prognosis, and 4) as potential therapies for metastatic bone cancer are discussed.

Gene of the month: Interleukin 6 (IL-6)

A better understanding of IL-6 and its role in various pathological conditions could enable the development of strategies to use it as a therapeutic target, as well as the therapeutic applications of anti-IL-6 agents.



Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.

In six clinical studies of mAbs to IL-6 with BE-8 or CNTO 328 in patients with multiple myeloma, renal cell carcinoma, and B-lymphoproliferative disorders, anti-IL-6 mAb treatment decreased C-reactive protein levels in all patients, and the antibodies were well tolerated, and no serious adverse effects were observed in the vast majority of studies.

IL-6 is required for glioma development in a mouse model

It is shown that ablation of IL-6 prevents tumour formation in these predisposed animals, but did not affect preneoplastic astrogliosis, and this findings indicate an important role for IL- 6 in the development and malignant progression of astrocytomas.

Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine.

The data indicate that ovarian tumor cells secreted IL-6, a highly angiogenic cytokine that supports progression of disease.

Human glioblastoma cells release interleukin 6 in vivo and in vitro.

Interleukin 6 (IL-6) production and release by human glioblastomas both in vitro and in vivo is demonstrated and the elevated levels of serum acute phase proteins and immune complexes found in glooblastoma patients may be the result of this secretion.

Interleukin-6 overexpression as a marker of malignancy in human gliomas.

It can be inferred that IL-6 gene expression is related to glioma aggressiveness and thatIL-6 may play a central role in GBM behavior, and Interleukin-6 could be considered as a new potential target in the treatment of GBMs.

Interleukin‐6 and its receptor in cancer

Early results in the clinic suggest that this strategy may have a significant salutary impact on diverse tumors, and there is preliminary evidence suggesting that targeting of the IL‐6 system may be beneficial in the treatment of cancer.

Interleukin‐6‐Mediated Autocrine Growth Promotion in Human Glioblastoma Multiforme Cell Line U87MG

The expression of IL‐6 by human fetal astrocytes in culture is highly suggestive of its role as an oncofetal protein responsible for rapid proliferation of fetal and tumor cells but not cells of adult brain.

Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases.

  • Y. Ohsugi
  • Biology, Medicine
    Biological & pharmaceutical bulletin
  • 2007
A study in mice demonstrated that IL-6 promotes the development of a new type of T-helper cells called Th17 cells that impact the pathogenesis of autoimmune diseases, suggesting that TCZ is not only an antiinflammatory agent but also might affect basic autoimmunity.

Interleukin-6-producing Cells in a Human Glioblastoma Cell Line are not Affected by Ionizing Radiation

It is suggested that this small (about 1%) fraction of G5 cells, constitutively producing IL-6, is highly radioresistant.